These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27281613)

  • 1. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
    Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
    Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
    Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
    Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells.
    Thiel U; Schober SJ; Einspieler I; Kirschner A; Thiede M; Schirmer D; Gall K; Blaeschke F; Schmidt O; Jabar S; Ranft A; Alba Rubío R; Dirksen U; Grunewald TGP; Sorensen PH; Richter GHS; von Lüttichau IT; Busch DH; Burdach SEG
    Oncoimmunology; 2017; 6(5):e1312239. PubMed ID: 28638739
    [No Abstract]   [Full Text] [Related]  

  • 4. Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells.
    Thiel U; Pirson S; Müller-Spahn C; Conrad H; Busch DH; Bernhard H; Burdach S; Richter GH
    Br J Cancer; 2011 Mar; 104(6):948-56. PubMed ID: 21407224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma.
    von Heyking K; Calzada-Wack J; Göllner S; Neff F; Schmidt O; Hensel T; Schirmer D; Fasan A; Esposito I; Müller-Tidow C; Sorensen PH; Burdach S; Richter GHS
    Mol Oncol; 2017 Sep; 11(9):1288-1301. PubMed ID: 28319320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma
    Kirschner A; Thiede M; Grünewald TG; Alba Rubio R; Richter GH; Kirchner T; Busch DH; Burdach S; Thiel U
    Oncoimmunology; 2017; 6(2):e1273301. PubMed ID: 28344885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.
    Biele E; Schober SJ; Prexler C; Thiede M; Heyking KV; Gassmann H; Eck J; Xue B; Burdach S; Thiel U
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC Class I-Restricted TCR-Transgenic CD4
    Schober SJ; Thiede M; Gassmann H; Prexler C; Xue B; Schirmer D; Wohlleber D; Stein S; Grünewald TGP; Busch DH; Richter GHS; Burdach SEG; Thiel U
    Cells; 2020 Jun; 9(7):. PubMed ID: 32610710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
    Schirmer D; Grünewald TG; Klar R; Schmidt O; Wohlleber D; Rubío RA; Uckert W; Thiel U; Bohne F; Busch DH; Krackhardt AM; Burdach S; Richter GH
    Oncoimmunology; 2016 Jun; 5(6):e1175795. PubMed ID: 27471654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
    Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
    Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
    Bullock TN; Mullins DW; Colella TA; Engelhard VH
    J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
    Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
    Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines.
    Meij P; Jedema I; Zandvliet ML; van der Heiden PL; van de Meent M; van Egmond HM; van Liempt E; Hoogstraten C; Kruithof S; Veld S; Marijt EW; von dem Borne PA; Lankester AC; Halkes CJ; Falkenburg JH
    J Immunother; 2012 Oct; 35(8):621-8. PubMed ID: 22996368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
    Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
    Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMV-specific TCR-transgenic T cells for immunotherapy.
    Schub A; Schuster IG; Hammerschmidt W; Moosmann A
    J Immunol; 2009 Nov; 183(10):6819-30. PubMed ID: 19864595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.